GSK Stands By Avandia: Seeks Label Change, Asks Docs To Give It Another Try

Armed with new safety data, GlaxoSmithKline says it remains committed to Avandia, with hopes of a fresh label from the FDA and a change of heart from doctors who had ditched the troubled type 2 diabetes drug